Tevogen Supports White House’s New AI Action Plan for Healthcare
Tevogen Bio Holdings Inc. has expressed strong support for the White House’s recent release of “Winning the Race: America’s AI Action Plan”, announced on July 23, 2025. The plan highlights the importance of creating standards tailored to specific domains, establishing regulatory sandboxes known as AI Centers of Excellence, and fostering collaboration through stakeholder meetings led by the National Institute of Standards and Technology (NIST).
This federal strategy aims to build trust, improve governance, and boost productivity in healthcare AI applications—areas that align closely with Tevogen’s current initiatives.
Advancing Healthcare AI with PredicTcell™
In line with the healthcare priorities set out in the AI Action Plan, Tevogen.AI recently developed the alpha version of PredicTcell™. This proprietary machine learning model, created in partnership with Microsoft and Databricks, significantly reduces the time needed for target analysis in immunotherapy research. By cutting weeks off this process, PredicTcell™ has the potential to save billions in drug development costs.
This progress reflects the Action Plan’s emphasis on accelerating scientific AI innovation and the practical adoption of AI technologies in healthcare.
Commitment to Accessible and Ethical AI Solutions
Ryan Saadi, MD, MPH, Founder and CEO of Tevogen, emphasized the company’s mission: “AI can lower both the cost and time required to deliver life-saving treatments to patients.” He praised the U.S. government’s recognition of AI’s potential and the establishment of a national strategy that balances innovation with equity.
Tevogen.AI is focused on creating scalable and ethical AI solutions that expand access to advanced and affordable therapeutics for all Americans.
Important Notice on Forward-Looking Statements
This article includes forward-looking statements regarding Tevogen’s plans and expectations about its research, manufacturing capabilities, and growth in the healthcare and biopharmaceutical industries. These statements involve risks and uncertainties that could cause actual outcomes to differ materially.
Factors that could impact results include the need for additional capital, market competition, regulatory changes, economic conditions, technological developments, and challenges in clinical trials and commercialization.
Readers should not place undue reliance on these forward-looking statements as they reflect management’s views as of the date of the announcement. Tevogen is not obligated to update these statements except as required by law.
Contact Information
Tevogen Bio Communications
Phone: 1 877 TEVOGEN, Ext 701
Email: Communications@Tevogen.com
Your membership also unlocks:
